Shaanxi Maikaoote Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Maikaoote") was established in January 2007 in Xi'an and has since expanded its operations to Xi'an, Suzhou, Beijing, Shanghai, Hong Kong, and the United States. The company is an innovative pharmaceutical technology enterprise focused on new drug development, striving to become a leading-edge pioneer in the research and development of bifunctional and multifunctional specific peptide therapeutics. Its R&D efforts are centered on novel drugs for cardiovascular and cerebrovascular diseases, metabolic disorders, and inflammatory‑pain‑related conditions. Committed to creating groundbreaking medicines that save lives and address unmet clinical needs, Maikaoote leverages scientific innovation to safeguard human health. As a platform‑based biotechnology company, Maikaoote is dedicated to accelerating the innovation and development of next‑generation bispecific and multispecific peptide therapeutics worldwide. Our core product candidates are currently in Phase III clinical trials. Since its founding in 2007, the company has concentrated on metabolic diseases—particularly kidney‑related conditions—and cardiovascular and cerebrovascular disorders. As a global pioneer in the concept of bispecific/multispecific peptide technologies, and backed by an extensive pipeline of candidates advancing into clinical development, Maikaoote has firmly established itself as a leader in this field.